Drugs / Pegylated interferon alfa-2a (PegIFNα-2a)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01616524 | Jul 2012 → Jun 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01846832 Background | Sep 2013 → Aug 2015 | chronic hepatitis C virus infection | Janssen-Cilag International NV | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated interferon alfa-2a (PegIFNα-2a) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01846832 ↗ |
| Known as | PegIFNα-2a | “Drug: Pegylated interferon alfa-2a (PegIFNα-2a)” NCT01846832 ↗ |
| Route | Subcutaneous | “180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection” NCT01846832 ↗ |